AB Science annonce q
AB Science annonce que Santé Canada a émis un Avis de Non-Conformité-Retrait (ANC-R) pour le masitinib dans la SLA
26 févr. 2024 12h32 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE SANTÉ CANADA A ÉMIS UN AVIS DE NON-CONFORMITÉ-RETRAIT (ANC-R) POUR LE MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE AB SCIENCE A L'INTENTION DE...
AB Science announces
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
26 févr. 2024 12h32 HE | AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS ISSUED A NOTICE OF NON-COMPLIANCE-WITHDRAWAL (NON/w) FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AB SCIENCE INTENDS TO SUBMIT A REQUEST...
Orphai071eFINAL Soc Med.jpg
OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union
15 févr. 2024 10h38 HE | OrphAI Therapeutics Inc.
GUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today...
2024 MDA Clinical & Scientific Conference Keynote Speaker is Brooke Eby
Brooke Eby, ALS Patient and Advocate, to deliver Keynote Address at 2024 MDA Clinical & Scientific Conference
15 févr. 2024 09h00 HE | Muscular Dystrophy Association
New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific...
AB Science announces
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
26 janv. 2024 12h01 HE | AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN...
AB Science fait le p
AB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des Médicaments
26 janv. 2024 12h01 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE AUPRÈS DE L'AGENCE EUROPÉENNE DES...
Orphai071eFINAL Soc Med.jpg
OrphAI Therapeutics Announces Oral Presentation and Posters at the 22nd Annual NEALS Conference
02 oct. 2023 11h38 HE | OrphAI Therapeutics Inc.
GUILFORD, Conn., Oct. 02, 2023 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today data...
Orphai071d FINAL low res.jpg
AI Therapeutics Announces Name Change to OrphAI Therapeutics
28 sept. 2023 11h38 HE | AI Therapeutics, Inc.
GUILFORD, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has...
Logo transparent PNG.png
PathMaker Neurosystems Announces Initiation of First-in-Human Trial in ALS for Non-Invasive Neuromodulation Device
14 sept. 2023 06h00 HE | PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
Emergen logo.png
Global Amyotrophic Lateral Sclerosis Market Size to Reach USD 1,034.7 Million in 2032 | Emergen Research
29 août 2023 08h56 HE | Emergen Research
Vancouver, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The worldwide market for amyotrophic lateral sclerosis achieved a size of USD 613.0 million in the year 2022. According to the most recent study...